cefoperazone + tazobactam

Cefoperazone + tazobactam is a fixed-dose combination of two agents: - **Cefoperazone** is a third-generation cephalosporin antibiotic that exerts its bactericidal effect by inhibiting bacterial cell wall synthesis. - **Tazobactam** is a β-lactamase inhibitor that protects cefoperazone from degradation by β-lactamase enzymes produced by resistant bacteria, thereby extending the antibacterial spectrum of cefoperazone to include organisms producing these enzymes. This combination is primarily indicated for moderate to severe infections caused by β-lactamase-producing bacteria resistant to cefoperazone alone. It has demonstrated high efficacy in respiratory tract infections, urinary and genital tract infections, intra-abdominal and pelvic infections, among others. The drug shows strong activity against Pseudomonas aeruginosa and extended-spectrum β-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae[1][5]. Clinical studies have shown high bacterial eradication rates (up to ~98% in some trials) for respiratory system infections[1]. The product was developed as an innovative new drug in China (notably at China Pharmaceutical University), with several patented formulations including unique ratios such as 6:1 or 8:1 (cefoperazone:tazobactam)[1][2]. It does not require dose adjustment in patients with severe renal impairment[1].

Brand names

COZOTAZMagnexZosynCefobactam

Other names

头孢哌酮他巴唑头孢哌酮钠他唑巴坦钠cefoperazone sodium and tazobactam sodium